Patents by Inventor Juan Luengo

Juan Luengo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • KRAS modulators and uses thereof
    Patent number: 11912723
    Abstract: Provided herein are KRAS modulating compounds, such as compounds of Formula (I), (II), (II*), (III) or pharmaceutically acceptable salts, solvates, stereoisomers, atom labelled, or tautomers of any of the foregoing, useful for modulating KRAS GD12 and/or other G12 mutants.
    Type: Grant
    Filed: July 31, 2023
    Date of Patent: February 27, 2024
    Assignee: QUANTA THERAPEUTICS, INC.
    Inventors: Hong Lin, Juan Luengo, Neil Johnson, Audrey Hospital
  • KRAS MODULATORS AND USES THEREOF
    Publication number: 20230374042
    Abstract: Provided herein are KRAS modulating compounds, such as compounds of Formula (I), (II), (II*), (III) or pharmaceutically acceptable salts, solvates, stereoisomers, atom labelled, or tautomers of any of the foregoing, useful for modulating KRAS GD12 and/or other G12 mutants.
    Type: Application
    Filed: July 31, 2023
    Publication date: November 23, 2023
    Inventors: Hong LIN, Juan LUENGO, Neil JOHNSON, Audrey HOSPITAL
  • Substituted Pyrrolo[2,3-D]Pyrimidines As Inhibitors Of Protein Arginine Methyl Transferase 5 (PRMT5)
    Publication number: 20230174539
    Abstract: The disclosure is directed to compounds of Formula (I) and Formula (II), Formula (I) and Formula (II) and pharmaceutically acceptable salts or solvates thereof. Pharmaceutical compositions comprising compounds of Formula (I) or Formula (II), as well as methods of their use and preparation, are also described.
    Type: Application
    Filed: December 12, 2022
    Publication date: June 8, 2023
    Inventors: Hong Lin, Michael Hawkins, Juan Luengo
  • Spiro-Sulfonamide Derivatives As Inhibitors Of Myeloid Cell Leukemia-1 (MCL-1) Protein
    Publication number: 20230010358
    Abstract: The disclosure is directed to compounds of Formula I Pharmaceutical compositions comprising compounds of Formula I as well as methods of their use and preparation, are also described.
    Type: Application
    Filed: August 17, 2021
    Publication date: January 12, 2023
    Inventors: Jincong Zhuo, Raul Leal, Rupa Shetty, Juan Luengo, Andrew Paul Combs, Peng Wei
  • Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of protein arginine methyl transferase 5 (PRMT5)
    Patent number: 11524962
    Abstract: The disclosure is directed to compounds of Formula (I) and Formula (II). Formula (I) and Formula (II) and pharmaceutically acceptable salts or solvates thereof. Pharmaceutical compositions comprising compounds of Formula (I) or Formula (II), as well as methods of their use and preparation, are also described.
    Type: Grant
    Filed: October 26, 2018
    Date of Patent: December 13, 2022
    Assignee: Prelude Therapeutics, Incorporated
    Inventors: Juan Luengo, Hong Lin, Michael Hawkins
  • Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5)
    Publication number: 20220218732
    Abstract: The disclosure is directed to methods of treating disease using compounds of Formula I, Formula II, Formula III, Formula IV, Formula V, or Formula VI:
    Type: Application
    Filed: April 3, 2020
    Publication date: July 14, 2022
    Inventors: Juan Luengo, Raul A. Leal, Hong Lin, Rupa Shetty, Krishna Vaddi
  • SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5)
    Publication number: 20220177481
    Abstract: The disclosure is directed to compounds of Formula I Pharmaceutical compositions comprising compounds of Formula I, as well as methods of their use and preparation, are also described.
    Type: Application
    Filed: February 17, 2022
    Publication date: June 9, 2022
    Inventors: Juan Luengo, Hong Lin, Michael Hawkins, Rupa Shetty, Philip Pitis, Gisela Saborit Villarroya
  • Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5)
    Publication number: 20220152073
    Abstract: The disclosure is directed to methods of treatment using compounds of Formula (I).
    Type: Application
    Filed: April 3, 2020
    Publication date: May 19, 2022
    Inventors: Hong Lin, Juan Luengo, Rupa Shetty, Michael Hawkins, Philip Pitis, Gisela Saborit Villarroya
  • Selective Inhibitors Of Protein Arginine Methytransterase 5 (PRMT5)
    Publication number: 20220153747
    Abstract: The disclosure is directed to compounds of Formula I Pharmaceutical compositions comprising compounds of Formula I, as well as methods of their use and preparation, are also described.
    Type: Application
    Filed: November 18, 2021
    Publication date: May 19, 2022
    Inventors: Hong Lin, Juan Luengo, Rupa Shetty, Michael Hawkins
  • Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5)
    Publication number: 20220152072
    Abstract: The disclosure is directed to methods of treating disease using compounds of Formula (I).
    Type: Application
    Filed: April 3, 2020
    Publication date: May 19, 2022
    Inventors: Hong Lin, Juan Luengo, Rupa Shetty, Michael Hawkins
  • Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
    Patent number: 11254683
    Abstract: The disclosure is directed to compounds of Formula I Pharmaceutical compositions comprising compounds of Formula I, as well as methods of their use and preparation, are also described.
    Type: Grant
    Filed: August 5, 2020
    Date of Patent: February 22, 2022
    Assignee: Prelude Therapeutics Incorporated
    Inventors: Juan Luengo, Hong Lin, Michael Hawkins, Rupa Shetty, Philip Pitis, Gisela Saborit Villarroya
  • Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
    Patent number: 11220524
    Abstract: The disclosure is directed to compounds of Formula I, Formula II, Formula III, Formula IV, Formula V, or Formula VI: Methods of their use in inhibiting a protein arginine methyltransferase 5 (PRMT5) enzyme and treating disease, as well as methods of their preparation are also described.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: January 11, 2022
    Assignee: Prelude Therapeutics Incorporated
    Inventors: Juan Luengo, Raul A. Leal, Hong Lin, Rupa Shetty, Krishna Vaddi
  • Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
    Patent number: 11214574
    Abstract: The disclosure is directed to compounds of Formula I Pharmaceutical compositions comprising compounds of Formula I, as well as methods of their use and preparation, are also described.
    Type: Grant
    Filed: June 1, 2020
    Date of Patent: January 4, 2022
    Assignee: Prelude Therapeutics, Incorporated
    Inventors: Juan Luengo, Hong Lin, Michael Hawkins, Rupa Shetty, Philip Pitis, Gisela Saborit Villarroya
  • SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5)
    Publication number: 20210403472
    Abstract: The disclosure is directed to compounds of Formula (I) and Formula (II). Formula (I) and Formula (II) and pharmaceutically acceptable salts or solvates thereof. Pharmaceutical compositions comprising compounds of Formula (I) or Formula (II), as well as methods of their use and preparation, are also described.
    Type: Application
    Filed: October 26, 2018
    Publication date: December 30, 2021
    Inventors: Juan LUENGO, Hong LIN, Michael HAWKINS
  • Selective inhibitors of protein arginine methytransterase 5 (PRMT5)
    Patent number: 11208416
    Abstract: The disclosure is directed to compounds of Formula I Pharmaceutical compositions comprising compounds of Formula I, as well as methods of their use and preparation, are also described.
    Type: Grant
    Filed: August 5, 2020
    Date of Patent: December 28, 2021
    Assignee: Prelude Therapeutics Incorporated
    Inventors: Hong Lin, Juan Luengo, Rupa Shetty, Michael Hawkins
  • Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (MCL-1) protein
    Patent number: 11130769
    Abstract: The disclosure is directed to compounds of Formula I Pharmaceutical compositions comprising compounds of Formula I as well as methods of their use and preparation, are also described.
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: September 28, 2021
    Assignee: Prelude Therapeutics, Incorporated
    Inventors: Jincong Zhuo, Raul Leal, Rupa Shetty, Juan Luengo, Andrew Paul Combs, Peng Wei
  • Selective inhibitors of protein arginine methlytransferase 5 (PRMT5)
    Patent number: 11078205
    Abstract: The disclosure is directed to compounds of Formula I Pharmaceutical compositions comprising compounds of Formula I, as well as methods of their use and preparation, are also described.
    Type: Grant
    Filed: January 16, 2020
    Date of Patent: August 3, 2021
    Assignee: Prelude Therapeutics, Incorporated
    Inventors: Hong Lin, Juan Luengo, Rupa Shetty, Michael Hawkins
  • SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5)
    Publication number: 20210130388
    Abstract: The disclosure is directed to compounds of Formula I, Formula II, Formula III, Formula IV, Formula V, or Formula VI: Methods of their use in inhibiting a protein arginine methyltransferase 5 (PRMT5) enzyme and treating disease, as well as methods of their preparation are also described.
    Type: Application
    Filed: February 20, 2018
    Publication date: May 6, 2021
    Inventors: Juan LUENGO, Raul A. LEAL, Hong LIN, Rupa SHETTY, Krishna VADDI
  • Selective Inhibitors Of Protein Arginine Methytransterase 5 (PRMT5)
    Publication number: 20200361946
    Abstract: The disclosure is directed to compounds of Formula I Pharmaceutical compositions comprising compounds of Formula I, as well as methods of their use and preparation, are also described.
    Type: Application
    Filed: August 5, 2020
    Publication date: November 19, 2020
    Inventors: Hong Lin, Juan Luengo, Rupa Shetty, Michael Hawkins
  • SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5)
    Publication number: 20200361945
    Abstract: The disclosure is directed to compounds of Formula I Pharmaceutical compositions comprising compounds of Formula I, as well as methods of their use and preparation, are also described.
    Type: Application
    Filed: August 5, 2020
    Publication date: November 19, 2020
    Inventors: Juan Luengo, Hong Lin, Michael Hawkins, Rupa Shetty, Philip Pitis, Gisela Saborit Villarroya